Shopping Cart
Remove All
Your shopping cart is currently empty
Sirtratumab
(Synonyms: Ha15-10ac12.1, Ha15-10ac12, AGS15C) Copy Product Info
🥰Excellent
Synonyms: Ha15-10ac12.1, Ha15-10ac12, AGS15C
Catalog No. T77381 Copy Product Info
🥰Excellent
Sirtratumab (also known as AGS15C / Ha15-10ac12) is a human monoclonal antibody targeting SLITRK6. It is used in cancer research, particularly in tumor models with high SLITRK6 expression, to investigate the role of SLITRK6 in tumor growth, proliferation, migration, and other biological processes. As a candidate antibody for ADC development, an antibody–drug conjugate derived from Sirtratumab (Sirtratumab vedotin / AGS15E) has been developed to selectively deliver cytotoxic agents to SLITRK6-positive tumor cells, thereby enhancing targeting specificity.
Sirtratumab
Cas No. 1824663-82-2
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $198 | - | In Stock | |
| 5 mg | $619 | - | In Stock | |
| 10 mg | $993 | - | In Stock | |
| 25 mg | $1,470 | - | In Stock | |
| 50 mg | $1,980 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:≥95% (SDS-PAGE); 98.78% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Sirtratumab (also known as AGS15C / Ha15-10ac12) is a human monoclonal antibody targeting SLITRK6. It is used in cancer research, particularly in tumor models with high SLITRK6 expression, to investigate the role of SLITRK6 in tumor growth, proliferation, migration, and other biological processes. As a candidate antibody for ADC development, an antibody–drug conjugate derived from Sirtratumab (Sirtratumab vedotin / AGS15E) has been developed to selectively deliver cytotoxic agents to SLITRK6-positive tumor cells, thereby enhancing targeting specificity. |
| Synonyms | Ha15-10ac12.1, Ha15-10ac12, AGS15C |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | SLITRK6 |
| Molecular Weight | ~150 kDa |
| Cas No. | 1824663-82-2 |
| Isotype | Human IgG2 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Preview
Related Tags: Sirtratumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.